|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, induced overexpression of miR-490-3p in GBM cell lines significantly inhibited key hallmarks including cellular proliferation, colony formation and spheroid formation, as well as epithelial-to-mesenchymal transition (EMT), with downregulation of multiple EMT transcription factors and promigratory genes (MMP9, CCL5, PIK3R1, ICAM1, ADAM17 and NOTCH1).
|
31008529 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunofluorescent (IF) staining was performed to observe the distribution of Notch1 and CXCR4 in GBM and GICs.
|
31382985 |
2019 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Notch1 is a prognostic factor that is distinctly activated in the classical and proneural subtype of glioblastoma and that promotes glioma cell survival via the NF-κB(p65) pathway.
|
29410396 |
2018 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry showed positive Notch1 expression in 71% (49/69) of GBM tissues.
|
29152141 |
2017 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the results of the present study suggested that upregulation of Notch1 is involved in the chemotherapy resistance and tumor recurrence of glioblastoma.
|
27315154 |
2016 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To determine the clinical importance of Notch-1 expression in glioblastoma, we analyzed 15 patients who had received bevacizumab therapy followed by a second surgery at recurrence.
|
25665548 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our current study was aim to investigate the clinical association between Notch-1 gene and EGFR gene as well as cell survival rate in human glioblastoma multiforme (GBM) samples.
|
25704190 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Of note, we identified a function for S518-Merlin, which is distinct from what has been reported when the expression of Merlin is diminished in relation to EGFR and NOTCH1 expression, providing first-time evidence that demonstrates that the phosphorylation of S518-Merlin in glioblastoma promotes oncogenic properties that are not only the result of inactivation of the tumor suppressor role of Merlin but also an independent process implicating a Merlin-driven regulation of NOTCH1 and EGFR.
|
25043298 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
A functional polymorphism in the pre‑miR‑146a gene influences the prognosis of glioblastoma multiforme by interfering with the balance between Notch1 and Notch2.
|
26165719 |
2015 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In human gliomas and primary cultures, Notch1 was moderate/strong in low-grade tumors but weak in glioblastoma multiforme (GBM).
|
24305720 |
2014 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We had knocked down Notch1 by siRNA in glioblastoma cells, and identified that the cell growth and invasion were inhibited, whereas cell apoptosis was induced either in vitro or in vivo.
|
23349727 |
2013 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that siRNA-mediated silencing of the Notch-1 gene may represent a novel target for gene therapy of GBM.
|
21667253 |
2012 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of the Notch1 pathway overcomes apoptosis resistance and sensitizes glioblastoma cells to apoptosis induced by ionizing radiation, the death ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) or the Bcl-2/Bcl-XL inhibitor ABT-737.
|
22249262 |
2012 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also show that KLF9 regulates GBM neurosphere cells by binding to the Notch1 promoter and suppressing Notch1 expression and downstream signaling.
|
21280156 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Morphological analysis confirmed inhibition of NICD when U251 MG cells were treated with puPA, puPAR or pU2. uPA/uPAR down regulation inhibited Notch 1 mRNA in all three examined cell lines. uPA/uPAR shRNA down regulated nuclear activation of NF-κB subunits and phosphorylation of AKT/mTOR pathway in U251 MG and GBM xenografts. puPA down regulated NICD and HES induced phosphorylation of AKT/ERK and NF-κB.
|
22004682 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme.
|
21743299 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, we confirmed the anti-proliferative and pro-apoptotic effects of resveratrol on glioblastoma cells and revealed Notch-1 activation-dependent restoration of p53 as an important causative mechanism.
|
21743969 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we quantified RNA expression levels of stem cell markers [CD133, Nestin, BMI-1, maternal embryonic leucine zipper kinase (MELK), and Notch1-4] as well as RTKs (EGFR, ErbB4, VEGFR1-3, FGFR1, -2, PDGFRΑ, and PDGFRΒ) in 42 clinical samples of glioblastoma by the real-time RT-PCR method.
|
21691733 |
2011 |
|
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
CTD_human |
Knockdown of individual Notch receptors revealed that Notch1 and Notch2 receptors differentially contributed to GBM cell growth, with Notch2 having a predominant role.
|
21127729 |
2010 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we show that hypoxia increases Notch1 activation, which in turn induces the expression of transient receptor potential 6 (TRPC6) in primary samples and cell lines derived from GBM.
|
20028870 |
2010 |
|
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis of Notch 1 expression and activation showed that Notch 1 protein was overexpressed and/or activated in Ras-transformed astrocytes, in three of four GBM cell lines, and in four of five primary GBM samples.
|
17367064 |
2007 |